Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Pilocarpine; Travoprost

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Chronic Angle Closure Glaucoma (CACG)

• 21-35 millimeters mercury mean intraocular pressure on Eligibility visit day at 9 AM

• Peripheral iridotomy performed ≥ 1 Month prior to the Screening visit

• Anterior chamber angle in which the trabecular meshwork is not visible for ≥180 degrees in gonioscopy without indentation

• Peripheral anterior synechiae (PAS)

Exclusion Criteria:

• Traumatic damage of the anterior chamber angle

• History of ocular inflammation or surgery (except for iridotomy) ≤ 3 months

• Patients who cannot be safely discontinued from use of all ocular hypotensive medication(s) for 12 days to 14 weeks

• Visual Acuity ≥ 1.0

• Contact lenses wearer